Description

Remo-M 500 Tablet 

Remo-M 500 Tablet is a combination oral antidiabetic medication designed for the management of type 2 diabetes mellitus. Each tablet contains Remogliflozin Etabonate 100 mg and Metformin Hydrochloride IP 500 mg. The combination provides dual action to help control blood glucose levels effectively in patients whose blood sugar is not adequately managed with diet, exercise, or monotherapy.

The tablet is film-coated, facilitating easy oral administration, protecting the active ingredients, and ensuring proper absorption.

. Composition

Excipients ensure stability, palatability, and controlled disintegration of the tablet.

. Mechanism of Action

A. Remogliflozin Etabonate (SGLT2 Inhibitor)

• Inhibits sodium-glucose co-transporter 2 in kidneys.

• Reduces glucose reabsorption in renal tubules.

• Promotes glucose excretion in urine.

• Lowers both fasting and postprandial blood glucose.

. Metformin Hydrochloride (Biguanide)

• Suppresses hepatic gluconeogenesis (glucose production in liver).

• Improves peripheral glucose uptake and insulin sensitivity.

• Does not stimulate insulin release, reducing risk of hypoglycemia.

The combination provides complementary mechanisms — renal glucose excretion and improved insulin sensitivity — for effective glycemic control.

. Pharmacokinetics

• Absorption: Both drugs are orally absorbed; Metformin absorption mainly in small intestine.

• Distribution: Metformin is minimally protein-bound; Remogliflozin binds moderately to plasma proteins.

• Metabolism: Remogliflozin is metabolized in liver; Metformin undergoes minimal hepatic metabolism.

• Excretion: Remogliflozin via urine and feces; Metformin excreted unchanged in urine.

• Half-life: Suitable for once or twice daily dosing, depending on physician’s prescription.

. Indications / Therapeutic Uses

• Type 2 diabetes mellitus patients inadequately controlled with diet and exercise.

• Can be used as initial combination therapy or add-on therapy to monotherapy.

• Helps lower fasting blood glucose, postprandial glucose, and HbA1c levels.

. Dosage and Administration

• Typical dose: one tablet orally, once or twice daily with meals (to reduce gastrointestinal side effects from Metformin).

• Swallow whole; do not chew or crush.

• Dosage may be adjusted based on renal function, age, or glycemic response.

. Benefits of Combination Therapy

• Dual mechanism of action: renal glucose excretion + insulin sensitization.

• Effective glycemic control: addresses both fasting and postprandial hyperglycemia.

• Convenience: two drugs in a single tablet.

• May help reduce dosage or side effects compared to higher doses of monotherapy.

. Side Effects

• Gastrointestinal: nausea, diarrhea, abdominal discomfort (mainly Metformin).

• Urinary tract infections or genital infections (Remogliflozin).

• Rare: lactic acidosis (mainly Metformin in renal impairment).

• Most side effects are mild and transient.

. Precautions

• Use caution in patients with renal impairment, liver disease, or history of recurrent UTIs.

• Monitor blood glucose and renal function regularly.

• Avoid dehydration; maintain adequate fluid intake.

• Not suitable for type 1 diabetes or diabetic ketoacidosis.

• Pregnancy and lactation: use only if prescribed.

. Storage Conditions

• Store in cool, dry place, below 30°C.

• Protect from light and moisture.

• Keep out of reach of children.

. Alternate Brand Options (Remogliflozin + Metformin Combination)

Prices are approximate; actual may vary by pharmacy and location.